Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5‐FU Chemotherapy in a Saudi Patient
Case Reports in Genetics · 2019-01 · 2019 (1)
DOI: 10.1155/2019/5150725 ↗Abstract
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5‐Fluorouracil (5‐FU) and its prodrug capecitabine. We report a 65‐year‐old female with rectal adenocarcinoma who experienced severe toxicities secondary to standard dose 5‐FU based chemotherapy. She was found to be heterozygous for rs371313778, c.2434G>A. This finding prompted restarting 5‐FU at 50% dose reduction with further titration in subsequent cycles. We herein report the first case of rs371313778, c.2434G>A (p.Val812lle) DPYD polymorphism leading to severe 5‐FU toxicities. The patient eventually completed a 6‐month course of adjuvant treatment with modification of 5‐FU dose.
EUVIMED